StockWireNews
Almost Here: Your $.35+ NASDAQ Biotech Stock Exhibits Big Upside Potential To Analyst's $5 Target
Gotta Do This: Sign-up Instructions For My SMS Updates Below
January 21st
Good Morning,
As good a year as 2019 was for the markets, it was an even better for many biotech stocks.
Biotech stocks are very sensitive to news. One major development -- such as a positive result from a clinical trial -- and share prices can take off in a hurry.
Digging through markets, I've uncovered a new NASDAQ biotech stock profile for today's trading session that I am compelled to bring to your attention.
At 9:30 AM EST today, I'll be bringing you a full report on this low float (under 7Mn shares) stock.
From its current trading levels just over $.35, it is displaying potential upside of over 1,200% to an analyst $5.00 price target.
If you aren't salivating yet, then you may want to consult a doctor!
For now, the best thing you can do to prepare is this one simple move: